Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HTT


Brief Information

Target Synonym:Huntingtin,HD protein,HD,HTT,Huntington Disease Protein,IT15,Huntingtin (Huntington Disease),LOMARS,Huntingtin Protein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
HTT-H51M5 Human Human HTT Protein, MBP,His Tag (MALS verified)
ACRO Quality

Part of Bioactivity data

HTT MALS images

The purity of Human HTT, MBP,His Tag (Cat. No. HTT-H51M5) is more than 85% and the molecular weight of this protein is around 62-80 kDa verified by SEC-MALS.

Synonym Name



Huntingtin is the protein coded for by the HTT gene. Autosomal dominant mutation in the Huntingtin (Htt) protein is the cause of Huntington’s Disease (HD). In HD, the polyglutamine (polyQ) domain  in the N-terminal sequenceof the protein is expanded beyond a threshold of 36 glutamines. mutant polyQ expansion strongly correlates in an inverse manner to disease age of onset.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tominersen RG-6042; RO-7234292; ISIS-443139 Phase 3 Clinical Ionis Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd Huntington Disease Details
WVE-003 WVE-003 Phase 2 Clinical Wave Life Sciences Ltd Huntington Disease Details
PTC-518 PTC-518 Phase 2 Clinical Ptc Therapeutics Inc Huntington Disease Details
ER-2001 ER2001; ER-2001 Phase 1 Clinical Shenzhen Aima Biotechnology Co Ltd Huntington Disease Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message